Consensus EPS · Q2 2026
-$0.05
Consensus revenue · Q2 2026
$0
Analysts
2
Expected report
Aug 11, 2026
What to watch
- Analyst ratings: Mixed
Analyst consensus
Based on estimates from 2 analysts.
| Metric | Low | Consensus | High |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| EPS | -$0.05 | -$0.05 | -$0.05 |
| EBITDA | $0 | $0 | $0 |
| EBIT | $0 | $0 | $0 |
| Net income | -$8.6M | -$7.8M | -$6.9M |
- Revenue$0
- EPS-$0.05
- EBITDA$0
- EBIT$0
- Net income-$7.8M
Estimate revisions
How analyst consensus estimates have changed over the past 90 days.
| Metric | Now | 30d ago | 60d ago | 90d ago | 30d Δ |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| EPS | -$0.05 | -$0.05 | — | — | +10.0% |
Community vs analysts
See how the TickerLeague crowd's forecast stacks up against Wall Street.
Be the first to predict
No community consensus for SELLAS Life Sciences Group (SLS) Q2 2026 yet. Make a prediction to start the crowd forecast.
Analyst price target
Based on price targets from 1 analyst.
- Low
- $25.00
- Consensus
- $25.00
- Median
- $25.00
- High
- $25.00
- Current
- $10.01
- Upside
- +149.8%
Upside calculated vs most recent trading price of $10.01.
Analyst ratings
Consensus: Buy — based on 5 analyst ratings.
24-month trend
Recent analyst actions
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 12, 2026 | Maxim Group | maintain | Buy | Buy |
| Jul 16, 2025 | Maxim Group | maintain | Buy | Buy |
| Nov 22, 2023 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Sep 7, 2023 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Nov 15, 2022 | Alliance Global Partners | maintain | Buy | Buy |
| Jun 28, 2022 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Jul 21, 2021 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Nov 18, 2019 | Oppenheimer | maintain | Outperform | Outperform |
| Nov 18, 2019 | Maxim Group | upgrade | Hold | Buy |
| Nov 18, 2019 | Alliance Global Partners | maintain | Buy | Buy |
- Mar 12, 2026Maxim GroupBuy
- Jul 16, 2025Maxim GroupBuy
- Nov 22, 2023Cantor FitzgeraldOverweight
- Sep 7, 2023Cantor FitzgeraldOverweight
- Nov 15, 2022Alliance Global PartnersBuy
- Jun 28, 2022Cantor FitzgeraldOverweight
- Jul 21, 2021Cantor FitzgeraldOverweight
- Nov 18, 2019OppenheimerOutperform
- Nov 18, 2019Maxim GroupBuy
- Nov 18, 2019Alliance Global PartnersBuy
Frequently asked questions
SELLAS Life Sciences Group (SLS) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
How this company returns cash to shareholders — buybacks, dividends, and stock splits.